D-0326-2022 Class III Terminated
FDA drug recall D-0326-2022 was initiated by Lupin Pharmaceuticals Inc. on Dec 22, 2021 and is designated Class III. Reason for recall: Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration. The recall status is terminated (terminated Sep 12, 2022). Affected quantity: 50,832 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 12, 2022
- Initiation Date
- Dec 22, 2021
- Termination Date
- Sep 12, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 50,832 bottles
Product description
Gatifloxacin Ophthalmic Solution, 0.5%, 2.5 mL bottle, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, INDIA, NDC 68180-435-01.
Reason for recall
Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.
Distribution pattern
Nationwide in the USA and Puerto Rico
Code information
Lot #: H003037, exp. date May 2022; H100132, exp. date June 2022; H100847, exp. date October 2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0326-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026